{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T20:08:40Z","timestamp":1791144520096,"version":"4.1.0"},"reference-count":28,"publisher":"American Association for Cancer Research (AACR)","issue":"2","license":[{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20K07652"],"award-info":[{"award-number":["JP20K07652"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chiba University Futuristic Medical Fund"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Invariant natural killer T (iNKT) cells play an essential role in antitumor immunity by exerting cytotoxicity and producing massive amounts of cytokines. iNKT cells express invariant T-cell receptors (TCR) to recognize their cognate glycolipid antigens such as \u03b1-galactosylceramide (\u03b1-GalCer) presented on CD1d. We recently reported that iNKT cells recognize CD1d-negative leukemia cell line K562 in a TCR-dependent manner. However, it remains controversial how iNKT cells use TCRs to recognize and exhibit cytotoxic activity toward CD1d-negative tumors cells without CD1d restriction. Here, we report that iNKT cells exerted cytotoxicity toward K562 cells via a carried over anti-V\u03b124 TCR mAb from positive selection by magnetic bead sorting. We found that addition of the anti-V\u03b124J\u03b118 TCR mAb (6B11 mAb) rendered iNKT cells cytotoxic to K562 cells in an Fc\u03b3RII (CD32)-dependent manner. Moreover, iNKT cells treated with 6B11 mAb became cytotoxic to other CD32+ cell lines (U937 and Daudi). In addition, iNKT cells treated with 6B11 mAb suppressed K562 cell growth in a murine xenograft model in vivo. These data suggest that anti-iNKT TCR mAb treatment of iNKT cells can be applied as a therapeutic strategy to treat CD32+ cancers such as leukemia, lymphoma, and lung cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Our findings unveiled that iNKT cells recognize and kill CD1d-negative target tumors via the anti-iNKT TCR mAb bound to CD32 at the tumor site, thereby bridging iNKT cells and CD1d-negative tumors. These findings shed light on the therapeutic potential of anti-iNKT TCR mAbs in NKT cell\u2013based immunotherapy to treat CD1d-negative CD32+ cancers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-23-0203","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T09:51:58Z","timestamp":1707213118000},"page":"446-459","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Anti-V\u03b124J\u03b118 TCR Antibody Tunes iNKT Cell Responses to Target and Kill CD1d-negative Tumors in an Fc\u03b3RII (CD32)-dependent Manner"],"prefix":"10.1158","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9607-4425","authenticated-orcid":true,"given":"Mariko","family":"Takami","sequence":"first","affiliation":[{"name":"1Department of Medical Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9148-2871","authenticated-orcid":true,"given":"Takahiro","family":"Aoki","sequence":"additional","affiliation":[{"name":"1Department of Medical Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3382-9299","authenticated-orcid":true,"given":"Katsuhiro","family":"Nishimura","sequence":"additional","affiliation":[{"name":"1Department of Medical Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan."},{"name":"2Department of Pediatric Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3936-834X","authenticated-orcid":true,"given":"Hidekazu","family":"Tanaka","sequence":"additional","affiliation":[{"name":"1Department of Medical Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan."},{"name":"3Department of Thoracic Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3715-9408","authenticated-orcid":true,"given":"Atsushi","family":"Onodera","sequence":"additional","affiliation":[{"name":"4Institute for Advanced Academic Research, Chiba University, Chiba, Japan."},{"name":"5Research Institute for Disaster Medicine, Chiba University, Chiba, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9332-3129","authenticated-orcid":true,"given":"Shinichiro","family":"Motohashi","sequence":"additional","affiliation":[{"name":"1Department of Medical Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,2,19]]},"reference":[{"key":"2024021914081308300_bib1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nri3174","article-title":"Targeting natural killer cells and natural killer T cells in cancer","volume":"12","author":"Vivier","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"2024021914081308300_bib2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nri1309","article-title":"NKT cells: what's in a name?","volume":"4","author":"Godfrey","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"2024021914081308300_bib3","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.3389\/fimmu.2019.01126","article-title":"alpha-GalCer and iNKT cell-based cancer immunotherapy: realizing the therapeutic potentials","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Immunol"},{"key":"2024021914081308300_bib4","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.3389\/fimmu.2017.01178","article-title":"Natural killer T cells in cancer immunotherapy","volume":"8","author":"Nair","year":"2017","journal-title":"Front Immunol"},{"key":"2024021914081308300_bib5","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.4049\/jimmunol.167.6.3114","article-title":"Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells","volume":"167","author":"Metelitsa","year":"2001","journal-title":"J Immunol"},{"key":"2024021914081308300_bib6","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3389\/fimmu.2018.02021","article-title":"Clinical application of iNKT cell-mediated anti-tumor activity against lung cancer and head and neck cancer","volume":"9","author":"Takami","year":"2018","journal-title":"Front Immunol"},{"key":"2024021914081308300_bib7","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1158\/1078-0432.CCR-16-0600","article-title":"Adoptive transfer of invariant NKT cells as immunotherapy for advanced melanoma: a phase I clinical trial","volume":"23","author":"Exley","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2024021914081308300_bib8","doi-asserted-by":"crossref","first-page":"e000316","DOI":"10.1136\/jitc-2019-000316","article-title":"Phase II study of alpha-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer","volume":"8","author":"Toyoda","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2024021914081308300_bib9","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.immuni.2018.03.009","article-title":"Unconventional T cell targets for cancer immunotherapy","volume":"48","author":"Godfrey","year":"2018","journal-title":"Immunity"},{"key":"2024021914081308300_bib10","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.4049\/jimmunol.0800126","article-title":"A phase I-II study of alpha-galactosylceramide-pulsed IL-2\/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer","volume":"182","author":"Motohashi","year":"2009","journal-title":"J Immunol"},{"key":"2024021914081308300_bib11","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1111\/cas.14428","article-title":"Activated invariant natural killer T cells directly recognize leukemia cells in a CD1d-independent manner","volume":"111","author":"Aoki","year":"2020","journal-title":"Cancer Sci"},{"key":"2024021914081308300_bib12","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/eji.200940278","article-title":"NKG2D performs two functions in invariant NKT cells: direct TCR-independent activation of NK-like cytolysis and co-stimulation of activation by CD1d","volume":"41","author":"Kuylenstierna","year":"2011","journal-title":"Eur J Immunol"},{"key":"2024021914081308300_bib13","doi-asserted-by":"crossref","first-page":"e201800195","DOI":"10.26508\/lsa.201800195","article-title":"Human NK cell development in hIL-7 and hIL-15 knockin NOD\/SCID\/IL2rgKO mice","volume":"2","author":"Matsuda","year":"2019","journal-title":"Life Sci Alliance"},{"key":"2024021914081308300_bib14","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/eji.200737389","article-title":"Selective activation, expansion, and monitoring of human iNKT cells with a monoclonal antibody specific for the TCR alpha-chain CDR3 loop","volume":"38","author":"Exley","year":"2008","journal-title":"Eur J Immunol"},{"key":"2024021914081308300_bib15","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1073\/pnas.1611776114","article-title":"Latently and uninfected healthcare workers exposed to TB make protective antibodies against Mycobacterium tuberculosis","volume":"114","author":"Li","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024021914081308300_bib16","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1002\/stem.2465","article-title":"Efficient regeneration of human valpha24(+) invariant natural killer T cells and their anti-tumor activity in vivo","volume":"34","author":"Yamada","year":"2016","journal-title":"Stem Cells"},{"key":"2024021914081308300_bib17","doi-asserted-by":"crossref","first-page":"e1546543","DOI":"10.1080\/2162402X.2018.1546543","article-title":"The novel agonistic iNKT-cell antibody NKT14m induces a therapeutic antitumor response against B-cell lymphoma","volume":"8","author":"Escriba-Garcia","year":"2019","journal-title":"Oncoimmunology"},{"key":"2024021914081308300_bib18","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3390\/cancers13020312","article-title":"Engineering anti-tumor monoclonal antibodies and Fc receptors to enhance ADCC by human NK cells","volume":"13","author":"Dixon","year":"2021","journal-title":"Cancers"},{"key":"2024021914081308300_bib19","doi-asserted-by":"crossref","first-page":"5640","DOI":"10.1182\/blood-2012-01-380121","article-title":"Properties of mouse and human IgG receptors and their contribution to disease models","volume":"119","author":"Bruhns","year":"2012","journal-title":"Blood"},{"key":"2024021914081308300_bib20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/antib9030034","article-title":"Monoclonal antibodies in cancer therapy","volume":"9","author":"Zahavi","year":"2020","journal-title":"Antibodies"},{"key":"2024021914081308300_bib21","first-page":"14","article-title":"Monoclonal antibodies in cancer therapy","volume":"12","author":"Scott","year":"2012","journal-title":"Cancer Immun"},{"key":"2024021914081308300_bib22","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3892\/ijo.2018.4661","article-title":"From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment (Review)","volume":"54","author":"Schirrmacher","year":"2019","journal-title":"Int J Oncol"},{"key":"2024021914081308300_bib23","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"2024021914081308300_bib24","first-page":"883","article-title":"Mogamulizumab-kpkc: a novel therapy for the treatment of cutaneous T-cell lymphoma","volume":"10","author":"Watson","year":"2019","journal-title":"J Adv Pract Oncol"},{"key":"2024021914081308300_bib25","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/j.biopha.2018.11.121","article-title":"The applications of anti-CD20 antibodies to treat various B cells disorders","volume":"109","author":"Payandeh","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"2024021914081308300_bib26","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3390\/biom12030358","article-title":"Anti-GD2 directed immunotherapy for high-risk and metastatic neuroblastoma","volume":"12","author":"Chan","year":"2022","journal-title":"Biomolecules"},{"key":"2024021914081308300_bib27","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13045-021-01160-9","article-title":"Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia","volume":"14","author":"Wang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2024021914081308300_bib28","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/cyto.b.22045","article-title":"A comparison and review of the flow cytometric findings in classic Hodgkin lymphoma, nodular lymphocyte predominant Hodgkin lymphoma, T cell\/histiocyte rich large B cell lymphoma, and primary mediastinal large B cell lymphoma","volume":"102","author":"Martig","year":"2022","journal-title":"Cytometry B Clin Cytom"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-23-0203\/3413508\/crc-23-0203.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/2\/446\/3416792\/crc-23-0203.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/2\/446\/3416792\/crc-23-0203.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T09:08:47Z","timestamp":1708333727000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/4\/2\/446\/734648\/Anti-V-24J-18-TCR-Antibody-Tunes-iNKT-Cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,19]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,19]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-23-0203","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.25245009","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25245006.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25245027","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25245012.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25245015.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25245021.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25245024.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25245015","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25245033.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25245033","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25245021","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25245030.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25245036.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25245018","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25245006","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25245027.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25245018.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25245036","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25245024","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25245009.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25245012","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25245030","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7080963.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.7080963","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,19]]}}}